Recanatini M - Search Results

1

Protein conformational transitions: the closure mechanism of a kinase explored by atomistic simulations.

Berteotti A, Cavalli A, Branduardi D, Gervasio FL, Recanatini M, Parrinello M. Berteotti A, et al. Among authors: recanatini m. J Am Chem Soc. 2009 Jan 14;131(1):244-50. doi: 10.1021/ja806846q. J Am Chem Soc. 2009. PMID: 19067513

2

Network modeling helps to tackle the complexity of drug-disease systems.

Recanatini M, Menestrina L. Recanatini M, et al. WIREs Mech Dis. 2023 Jul-Aug;15(4):e1607. doi: 10.1002/wsbm.1607. Epub 2023 Mar 23. WIREs Mech Dis. 2023. PMID: 36958762 Review.

3

A comparative QSAR analysis of acetylcholinesterase inhibitors currently studied for the treatment of Alzheimer's disease.

Recanatini M, Cavalli A, Hansch C. Recanatini M, et al. Chem Biol Interact. 1997 Aug 1;105(3):199-228. doi: 10.1016/s0009-2797(97)00047-1. Chem Biol Interact. 1997. PMID: 9291997

4

Comparative molecular field analysis of non-steroidal aromatase inhibitors: an extended model for two different structural classes.

Recanatini M, Cavalli A. Recanatini M, et al. Bioorg Med Chem. 1998 Apr;6(4):377-88. doi: 10.1016/s0968-0896(97)10053-0. Bioorg Med Chem. 1998. PMID: 9597182

5

Acetylcholinesterase inhibitors for potential use in Alzheimer's disease: molecular modeling, synthesis and kinetic evaluation of 11H-indeno-[1,2-b]-quinolin-10-ylamine derivatives.

Rampa A, Bisi A, Belluti F, Gobbi S, Valenti P, Andrisano V, Cavrini V, Cavalli A, Recanatini M. Rampa A, et al. Among authors: recanatini m. Bioorg Med Chem. 2000 Mar;8(3):497-506. doi: 10.1016/s0968-0896(99)00306-5. Bioorg Med Chem. 2000. PMID: 10732965

6

[4-[[N-(3-chlorophenyl)carbamoyl]oxy]-2-butynyl]-trimethylammonium (McN-A-343)-related compounds. Effect of the butynyl chain inclusion into an aromatic unit on the potency for muscarinic receptors.

Tumiatti V, Angeli P, Andrisano V, Bolognesi ML, Cavalli A, Marucci G, Minarini A, Recanatini M, Rosini M, Melchiorre C. Tumiatti V, et al. Among authors: recanatini m. Bioorg Med Chem. 2000 Apr;8(4):681-9. doi: 10.1016/s0968-0896(99)00309-0. Bioorg Med Chem. 2000. PMID: 10819156

7

Linking CoMFA and protein homology models of enzyme-inhibitor interactions: an application to non-steroidal aromatase inhibitors.

Cavalli A, Greco G, Novellino E, Recanatini M. Cavalli A, et al. Among authors: recanatini m. Bioorg Med Chem. 2000 Dec;8(12):2771-80. doi: 10.1016/s0968-0896(00)00203-0. Bioorg Med Chem. 2000. PMID: 11131168

8

Acetylcholinesterase inhibitors: SAR and kinetic studies on omega-[N-methyl-N-(3-alkylcarbamoyloxyphenyl)methyl]aminoalkoxyaryl derivatives.

Rampa A, Piazzi L, Belluti F, Gobbi S, Bisi A, Bartolini M, Andrisano V, Cavrini V, Cavalli A, Recanatini M, Valenti P. Rampa A, et al. Among authors: recanatini m. J Med Chem. 2001 Nov 8;44(23):3810-20. doi: 10.1021/jm010914b. J Med Chem. 2001. PMID: 11689067

9

Imidazo[2,1 -b]thiazolylmethylene- and indolylmethylene-2-indolinones: a new class of cyclin-dependent kinase inhibitors. Design, synthesis, and CDK1/cyclin B inhibition.

Andreani A, Cavalli A, Granaiola M, Leoni A, Locatelli A, Morigi R, Rambaldi M, Recanatini M, Garnier M, Meijer L. Andreani A, et al. Among authors: recanatini m. Anticancer Drug Des. 2000 Dec;15(6):447-52. Anticancer Drug Des. 2000. PMID: 11716438

10

Three-dimensional model of the cyclin-dependent kinase 1 (CDK1): Ab initio active site parameters for molecular dynamics studies of CDKS.

Cavalli A, Dezi C, Folkers G, Scapozza L, Recanatini M. Cavalli A, et al. Among authors: recanatini m. Proteins. 2001 Dec 1;45(4):478-85. doi: 10.1002/prot.10013. Proteins. 2001. PMID: 11746695

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

150 results

Search Page

Filters